 Cyclophosphamide
"Cyclophosphamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
| Descriptor ID |
D003520
|
| MeSH Number(s) |
D02.455.526.728.650.730.243 D02.705.672.500.243
|
| Concept/Terms |
Cyclophosphamide- Cyclophosphamide
- Cytophosphane
- Cyclophosphamide Monohydrate
- Monohydrate, Cyclophosphamide
- Cyclophosphane
|
Below are MeSH descriptors whose meaning is more general than "Cyclophosphamide".
Below are MeSH descriptors whose meaning is more specific than "Cyclophosphamide".
This graph shows the total number of publications written about "Cyclophosphamide" by people in this website by year, and whether "Cyclophosphamide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 3 | 3 | | 1997 | 1 | 3 | 4 | | 1998 | 0 | 3 | 3 | | 2000 | 1 | 3 | 4 | | 2001 | 0 | 4 | 4 | | 2002 | 0 | 2 | 2 | | 2003 | 2 | 3 | 5 | | 2004 | 1 | 1 | 2 | | 2005 | 1 | 2 | 3 | | 2006 | 0 | 4 | 4 | | 2007 | 0 | 4 | 4 | | 2008 | 1 | 6 | 7 | | 2009 | 2 | 4 | 6 | | 2010 | 0 | 5 | 5 | | 2011 | 2 | 7 | 9 | | 2012 | 1 | 4 | 5 | | 2013 | 0 | 2 | 2 | | 2014 | 1 | 9 | 10 | | 2015 | 0 | 2 | 2 | | 2016 | 1 | 5 | 6 | | 2017 | 1 | 9 | 10 | | 2018 | 1 | 4 | 5 | | 2019 | 1 | 6 | 7 | | 2020 | 2 | 8 | 10 | | 2021 | 0 | 10 | 10 | | 2022 | 0 | 8 | 8 | | 2023 | 0 | 9 | 9 | | 2024 | 2 | 7 | 9 | | 2025 | 1 | 6 | 7 | | 2026 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cyclophosphamide" by people in Profiles.
-
Lerman BJ, King M, Mody R, Onyeama SJ, Marachelian A, Cash T, Federico SM, Granger M, Desai AV, Shusterman S, Foster JH, Sokol E, Greer C, Streby K, Meany HJ, Vo KT, Macy ME, Bagatell R. Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer. 2026 May; 73(5):e70195.
-
Atkinson MA, Chang JC, Davies AG, Maltenfort M, Luna IY, Scobell R, Mitsnefes M, Stotter BR, Dharnidharka VR, Dixon BP, Flynn JT, Gluck C, Kallash M, Smoyer WE, Razzaghi H, Bailey LC, Furth SL, Forrest CB, Denburg MR, Wenderfer SE. Using a multi-institutional pediatric learning health system to characterize induction therapy for incident lupus nephritis in children. Pediatr Nephrol. 2026 Apr; 41(4):1045-1053.
-
Hess B, Moskowitz A, Davis JA, Strati P, Sawalha Y, Bakos J, Sorrell M, Ferreira AC, Escribano-Serrat S, De Castro M, Brooks TR, Hill BT, Shah GL, Falade AS, Merryman R, Kamdar M, Ip A, Nachar V, Bennett JG, Lux N, Ahmed N, Hoffmann M, LaCasce A. Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R. Haematologica. 2026 Apr 01; 111(4):1389-1395.
-
Mondello P, Negaard B, Feldman AL, Link BK, Casulo C, Chihara D, Russler-Germain D, Romancik J, Gribbin C, Haddadi S, Mou E, Micallef IN, Johnston PB, Novak J, Wang Y, King RL, Novak AJ, Habermann TM, Martin P, Kahl B, Nowakowski GS, Nastoupil LJ, Cerhan JR, Flowers CR, Lossos IS, Burack RW, Maurer MJ, Ansell SM. Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts. Blood Cancer J. 2025 Aug 08; 15(1):134.
-
Matson SM, Kim GHJ, Humphries SM, Roth MD, Goldin J, Tashkin DP, Leng M, England BR, Lee JS, Volkmann ER. Impact of quantitative radiological features of interstitial lung disease on immunomodulatory treatment response in three autoimmune interstitial lung disease cohorts. Thorax. 2025 07 15; 80(8):540-546.
-
Kawano M, McKey J, Batchvarov IS, Capel B. Granulosa cell death is a significant contributor to DNA-damaging chemotherapy-induced ovarian insufficiency?. Biol Reprod. 2025 May 13; 112(5):906-915.
-
DuBois SG, Ogawa C, Moreno L, Mossé YP, Fischer M, Ryan AL, Vo KT, De Wilde B, Rubio-San-Simon A, Macy ME, Howell L, Shusterman S, Corradini N, Luksch R, Aerts I, Foster JH, Weiss BD, Karthik CP, Yuen E, Avsar E, Park JR, Marachelian A. A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.
-
Georges GE, Khanna D, Wener MH, Mei MG, Mayes MD, Simms RW, Sanchorawala V, Hosing C, Kafaja S, Pawarode A, Holmberg LA, Kolfenbach J, Furst DE, Sullivan KM, Huang S, Gooley T, Nash RA. Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial. Arthritis Rheumatol. 2025 May; 77(5):571-581.
-
Hill CS, Parkinson R, Jaffee EM, Sugar E, Zheng L, Onners B, Weiss MJ, Wolfgang CL, Cameron JL, Pawlik TM, Rosati L, Le DT, Hacker-Prietz A, Lutz ER, Schulick R, Narang AK, Laheru DA, Herman JM. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic Ductal Adenocarcinoma. Int J Radiat Oncol Biol Phys. 2025 Mar 15; 121(4):930-941.
-
Allen J, Abbott D, Eskandar J, Bair SM, Haverkos B, Jasem J, Kamdar M, Major A. DA-R-EPOCH May Mitigate the Adverse Prognostic Implication of the Diagnosis-to-Treatment Interval (DTI) in Large B-Cell Lymphomas. Clin Lymphoma Myeloma Leuk. 2025 Jan; 25(1):e26-e33.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|